Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials
Jeffrey T. Guptill(Duke University), Henry J. Kaminski(George Washington University), James F. Howard(University of North Carolina at Chapel Hill), Katherine Ruzhansky(Medical University of South Carolina), Carolina Barnett‐Tapia(Duke University), Mazen M. Dimachkie(University of Kansas Medical Center), Ik Jae Lee(Duke University), Richard J. Nowak(Yale University), Ali A. Habib(University of California, Irvine Medical Center), Volkan Granit(Biohaven Pharmaceuticals (United States)), Michael Benatar(Duke University), Gary Cutter(Epilepsy Foundation)
Cited by 26
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
|Annals of Neurology|1997|368
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis
|Annals of Neurology|2010|365